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Objective: To determine the clinical and molecular features in patients with amyotrophic lateral sclerosis 4 (ALS4) due
to mutations in the senataxin (SETX) gene and to develop tools for evaluating SETX variants.
Methods: Our study involved 32 patients, including 31 with mutation in SETX at c.1166 T>C (p.Leu389Ser) and 1 with
mutation at c.1153 G>A (p.Glu385Lys). Clinical characterization of the patients included neurological examination,
blood tests, magnetic resonance imaging (MRI), and dual-energy x-ray absorptiometry (DEXA). Fibroblasts and motor
neurons were obtained to model the disease and characterize the molecular alteration in senataxin function.
Results: We report key clinical features of ALS4. Laboratory analysis showed alteration of serum creatine kinase and
creatinine in the Leu389Ser ALS4 cohort. MRI showed increased muscle fat fraction in the lower extremities, which cor-
relates with disease duration (thigh fat fraction R2 = 0.35, p = 0.01; lower leg fat fraction R2 = 0.49, p < 0.01). DEXA
measurements showed lower extremities are more affected than upper extremities (average fat z scores of 2.1 and 0.6,
respectively). A cellular assay for SETX function confirmed that like the Leu389Ser mutation, the Glu385Lys variant
leads to a decrease in R loops, likely from a gain of function.
Interpretation: We identified clinical laboratory and radiological features of ALS4, and hence they should be moni-
tored for disease progression. The molecular characterization of R-loop levels in patient-derived cells provides insight
into the disease pathology and assays to evaluate the pathogenicity of candidate mutations in the SETX gene.
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Amyotrophic lateral sclerosis (ALS) is a collection of neu-rodegenerative disorders characterized by loss of upper
and lower motor neurons. A subgroup of ALS has been found
to be caused by genetic mutations.1 Among the mutated
genes are those that encode RNA processing proteins, includ-
ing TDP-43, FUS, hnRNPA1, and hnRNPA2B1.2–4 Identi-
fication of these mutations has improved our understanding
of how RNA synthesis and post-transcriptional processing
affect motor neuron pathophysiology.
There is a range of manifestations in ALS, including
age of onset and rate of progression. The heterogeneity poses
diagnostic challenges and impedes patient care. As genetic
testing has become more available, more diagnoses of
genetic forms of the disease have been made. However,
interpretation of the results is not always simple. Even when
the results are clear, most of the genetic forms of ALS are
rare, and the clinical course and manifestations are not well
characterized. This lack of information hampers genetic
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counseling and assessment of disease prognosis, and it limits
evaluation of outcome in clinical trials.
A genetic form of ALS that faces these challenges is
ALS4, an autosomal dominant disorder caused by muta-
tions in the senataxin (SETX) gene.5–8 SETX is a large
gene that encodes a 303 kD helicase, which resolves
RNA–DNA hybrids. It is often difficult to determine
whether a particular sequence variant is pathogenic, as
affected family members may not be available for segrega-
tion analysis or the variant may be a de novo mutation.
Here we examined and followed patients from 1 large
ALS4 pedigree and 1 unrelated patient to characterize the
clinical signs, identify biomarkers, and develop a molecu-




SETX mutations were confirmed in 31 patients with the
mutation Leu389Ser and 1 patient with the variant
Glu385Lys. All subjects received clinical evaluations at the
National Institutes of Health (NIH) in Bethesda, Mary-
land, under institutional review board–approved protocol
00-N-0043 Clinical and Molecular Manifestations of
Inherited Neurological Disorders. Written informed con-
sent was received from all participants before inclusion in
the study. Laboratory testing and clinical evaluations were
done at the NIH clinical center. Muscle strength was eval-
uated using the Medical Research Council (MRC) scale.
Radiological Testing
Seventeen ALS4 patients (10 female, 7 male) underwent
T1-weighted 1.5-T magnetic resonance imaging (MRI) of
the leg at the NIH clinical center. Nine of these subjects
(5 female, 4 male) had follow-up MRI. Images for thigh
muscle quantification included a 10cm region around the
midpoint between the head of the femur and the cartilage
meniscus of the knee. For the lower leg, the quantified
images included a 6cm region around a point one-third of
the distance from the cartilage meniscus of the knee to the
articular cartilage of the tibial–talus joint. A semiautomated
code with Fiji software was used to quantify the area of con-
tractile (hypointense) and noncontractile (hyperintense) tis-
sue with the “auto local threshold” function and the
Phansalkar method for each image sequence.9 Manual
image segmentation of tissue area was done for bone mar-
row, compact bone, and subcutaneous adipose tissue in each
image. Fat fraction was calculated as the ratio of
noncontractile tissue to total tissue area in the thigh muscle
and leg muscle compartments.
Dual-energy x-ray absorptiometry (DEXA) whole-
body composition measurements were obtained at NIH
Clinical Center Radiology, and z scores were calculated
using normative data from the National Health and
Nutrition Examination Survey dataset.10
Motor Neuron Characterization
Induced pluripotent stem cells (iPSCs) were generated from
dermal fibroblasts from biopsy of the ventral forearm from
2 healthy controls. Fibroblasts were cultured as previously
described.11 A third control iPSC line (WTC11) was
obtained from the Coriell Institute for Medical Research.
Stem cells were differentiated into motor neuron–like cells by
stable insertion of an inducible transcription factor cassette
expressing neurogenin-2 (NGN2), islet-1 (ISL1), and LIM
homeobox 3 (LHX3; hNIL) into the CLYBL safe harbor
locus as previously described.12 Differentiation was initiated
using Dulbecco modified Eagles medium (DMEM)/F12
containing N2 supplement, nonessential amino acids, L-glu-
tamine, 10μM ROCK inhibitor, 0.2μM compound E, and
2μg/ml doxycycline. After 2 days of differentiation, the cells
were dissociated with accutase and plated on poly-l-orni-
thine–coated dishes in DMEM/F12 media containing N2
supplement, nonessential amino acids, L-glutamine, B27
supplement, 10ng/ml brain-derived neurotrophic factor, and
1μg/ml laminin (density of 10,000 cells per well of a 96-well
plate for TGF-β characterization). The cells were treated with
TGF-β (20ng/ml; R&D Systems, Minneapolis, MN) begin-
ning at 2 days of differentiation with 50% media changes at
2-day intervals. Morphologic analysis was done on images
acquired with a 20× objective and Ti-E motorized fluores-
cence microscope (Nikon Instruments, Melville, NY).
Nikon’s NIS-Element Advanced Research (AR) software was
used to mask the cell somas and neurites. Neurite length and
number of branch points were quantified from 5 wells
(25 images/well) of a 96-well plate for each sample and nor-
malized to the soma count.
Senataxin Assays
Control fibroblasts were transfected with plasmids
corresponding to wild type (WT) and SETX variants for
1 day before collection and S9.6 dot blot. Samples for
immunofluorescence were fixed 2 days after transfection
with 4% paraformaldehyde for 15 minutes at room temper-
ature, and motor neurons were fixed for 10 minutes with
4% paraformaldehyde containing 4% sucrose and then
quenched in 100mM glycine for 5 minutes. Fixed cells were
then washed 3 times with phosphate-buffered saline (PBS)
as previously described.11 The cells were stained with the
following antibodies: S9.6 antibody (gift from Stephen
Leppla), 1:500 HB9 antibody (Developmental Studies
Hybridoma Bank, Iowa City, IA), 1:500 SETX (Novus Bio-
logical, Littleton, CO), or 1:2,000 SMI-32 (Abcam,
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Cambridge, UK). Quantification of staining by ImageJ was
done by observers blinded to the genotypes of the samples.
S9.6 Dot Blot
Genomic DNA was phenol extracted, ethanol precipitated,
and reconstituted in 12μl Tris-EDTA buffer. Then 2μl
DNA solution (100ng) was loaded to Hybond N+ nylon
membrane (GE Healthcare Life Sciences, Issaquah, WA)
presoaked with PBS and crosslinked in UV Stratalinker
2400 (Stratagene, La Jolla, CA) at the “Auto Crosslink” set-
ting (1,200μJ × 100). The membrane was blocked in 5%
milk in Tris-buffered saline–0.05% Tween-20 for 1 hour
and incubated with 1:1,000 S9.6 antibody overnight at 4C
to detect RNA–DNA hybrids. A duplicate blot was incu-
bated with anti–double stranded (ds) DNA antibody
(Abcam) as loading control. The dsDNA, dsRNA, and
RNA–DNA hybrid controls were annealed using synthetic
oligos reported previously.13 Single-stranded (ss) RNA, top
strand: 50-UGGGGGCUCGUCCGGGAUAUGGGAAC
CACUGAUCCC-30; ssDNA, top strand: 50-TGGGGGCTC
GTCCGGGATATGGGAACCACTGATCCC-30; ssDNA,
bottom strand: 50-GGGATCAGTGGTTCCCATATCCCG
GACGAGCCCCCA-30; and ssRNA, bottom strand: 50-GGG
AUCAGUGGUUCCCAUAUCCCGGACGAGCCCCCA-30.
Messenger RNA Expression and Western Blot
Analysis
RNA was extracted and analyzed as previously described.11
Briefly, 1μg total RNA was converted to complementary
DNA using the High Capacity cDNA Reverse Transcriptase
kit (Applied Biosystems, Foster City, CA), and BAMBI
expression levels were evaluated with TaqMan probe (Applied
Biosystems; Hs03044164_m1) with HPRT1 TaqMan probe
(Hs02800695_m1) as a control. Western blots were done
with antibodies for SETX (Bethyl laboratories, Montgomery,
TX), pSMAD2, and SMAD2/3 (Cell Signaling Technology,
Danvers, MA), vinculin (Abcam), and lysates prepared in
radioimmunoprecipitation assay buffer (50mM Tris pH
8, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulfate).
Results
Genetic Evaluation
Thirty of the 31 subjects were members of a large pedigree.6
All affected members were confirmed to have the Leu389Ser
mutation in SETX. Another unrelated patient was evaluated
for a history of difficulty with walking since age 4 years,
necessitating the use of leg braces at age 8 years. She had
developed hand weakness at age 10 years. Genetic testing
identified a Glu385Lys (heterozygous c.1153 G>A) change
close to the previously described SETX mutation. The vari-
ant was not present in the Exome Aggregation Consortium
(ExAC) sequencing database and predicts substitution of an
amino acid conserved across mammalian species (Fig 1A,
B). We previously showed that the Leu389Ser mutation
does not affect senataxin expression.11 We found similar
SETX protein expression and cellular localization in
Glu385Lys patient cells as in cells from 2 unrelated controls
(see Fig 1C, D).
Physical Examination
The demographics of the 31 patients (14 male, 17 female)
with Leu389Ser ALS4 in this study are shown in the Supple-
mentary Table. The average age at the time of evaluation
was 42 years. Sixty-five percent of patients reported having
at least 1 fall within the past year. The average age of onset
of weakness was 16 years. On physical examination, a
majority of patients (87%) was found to have hyperreflexia,
and 7 (23%) had a Babinski reflex. Manual muscle strength
testing using the MRC scale was done on all 31 patients,
FIGURE 1: Glu385Lys mutation in senataxin (SETX). (A) The
amino acid sequence at position 385 of SETX is conserved
across species. (B) Map of helicase domain and nuclear
localization signal (NLS) showing the location of the
3 previously known mutations causing amyotrophic lateral
sclerosis 4 (Tyr3Ile, Leu389Ser, and Arg2136His) and the
Glu385Lys variant. (C) Western blot of SETX from fibroblast
cultures of 2 controls and the Glu385Lys patient. Vinculin
was used as a loading control. (D) Immunofluorescence
staining for SETX (green) in 2 controls and patient
fibroblasts; 40,6-diamidino-2-phenylindole (DAPI) staining in
blue. Scale bar = 5μm. (E) Atrophy in the interossei muscles
of the hand and involuntary abduction of the fifth finger.
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including 14 who had additional follow-up visits over an
average of 3 years. Muscle weakness was found in 24 patients
(77%) and muscle wasting in 19 (61%). The pattern of
weakness was mostly symmetric, with evidence of asymme-
try (greater than 1 unit MRC difference between the left
and right side) in only 3 patients. Of the 24 patients with
extremity weakness, 14 had both proximal and distal
involvement, and the remaining 10 had only a distal distri-
bution. None of the patients had proximal weakness only.
With increasing disease duration, we found progressive
reduction in ankle dorsiflexion (R2 = 0.31, p < 0.0001) and
plantar flexion (R2 = 0.12, p < 0.01). Seven patients had
decreased sensation to at least 1 modality with a distal
pattern of involvement. Three patients reported mild symp-
toms of dysphagia with infrequent choking, and no patients
were found to have dysarthria. Only 1 patient was found to
have bulbar weakness with involvement of the orbicularis
oris and hypoglossal muscles. Additionally, evidence of
ataxia with dysmetria or past pointing in the upper extremi-
ties was found in about half of the patients. Evidence of ocu-
lar apraxia was detected in only 2 patients.
The patient with Glu385Lys SETX variant was
found to have atrophy and weakness in her distal upper
and lower extremities (see Fig 1E). She was unable to
extend her fingers against gravity and had no movement
in her ankles or toes. Reflexes were brisk diffusely in her
FIGURE 2: Clinical measurements in amyotrophic lateral sclerosis 4 (ALS4) patients with mutation at codon 389 (A-E) and codon
385 (F). (A) T1 magnetic resonance image (MRI) of the thigh muscle with segmented noncontractile tissue in black. Compact
bone and bone marrow removed from fat fraction calculation. (B) Disease duration is significantly correlated with MRI muscle fat
fraction from the thigh (R2 = 0.35; p = 0.01) and lower leg (R2 = 0.49; p < 0.01). (C) Dual-energy x-ray absorptiometry in an ALS4
patient showing relative preservation of lean body mass (red) in the upper compared to the lower extremities. (D) Distribution of
z scores shows a significant reduction in appendicular lean body mass (−1.7) and increase (E) in average leg (2.1) versus arm (0.6)
fat z scores. Z scores calculated using National Health and Nutrition Examination Survey reference controls. Black dotted line
indicates the z score 1 standard deviation below (D) or above (E) the mean. (F) T1 MRI of the thigh showing fatty infiltration and
loss of contractile tissue in the thigh (left) and lower leg (right) in a patient with mutation at codon 385. L = left; R = right.
550 Volume 87, No. 4
ANNALS of Neurology
upper and lower extremities, and plantar reflexes were
absent.
Laboratory Findings
Laboratory analysis showed a significant increase in serum
creatine kinase (CK) in both males (ALS4 mean 420U/
l  105 [standard error of the mean (SEM)], n = 11; vs con-
trol mean 177U/l  3, n = 1,141; p < 0.0001) and females
(ALS4 mean 182U/l  42, n = 11; vs control mean 106U/
l  3, n = 491; p < 0.0001). The male subjects also had a sig-
nificant decrease in creatinine levels compared to healthy con-
trols (ALS4 mean 0.56mg/dl  0.09, n = 8; vs control mean
1.02mg/dl  0.03, n = 73; p < 0.0001). There were no sig-
nificant differences in the serum sex hormone levels in the
male or female Leu389Ser ALS patients compared to con-
trols. The Glu385Lys ALS4 patient had normal CK and
reduced creatinine levels (0.33mg/dl).
Electrophysiology
Nerve conduction studies and electromyography in
13 patients with Leu389Ser and 1 patient with Glu385Lys
showed prolonged distal motor latencies, decreased ampli-
tudes of compound muscle action potential, and chronic
neurogenic changes. A length-dependent sensory neuropa-
thy was detected in 1 patient.
Radiographic Findings
To determine the extent of muscle damage, we used quantita-
tive MRI to measure fat replacement of skeletal muscle.
T1-weighted scans of the lower extremities were performed
on 17 patients. The results showed a positive correlation
between disease duration and muscle fat fraction in the thigh
(R2 = 0.35, p = 0.01) and lower leg (R2 = 0.49, p < 0.01; Fig 2)
consistent with muscle atrophy. We measured bone densi-
tometry and lean body mass in 12 subjects with DEXA. Half
FIGURE 3: TGF-β activity in patient fibroblasts and motor neuron characterization. (A) Reduced BAMBI transcript expression in
Glu385Lys patient fibroblasts compared to 2 controls. Error bars are standard error of the mean of triplicates. **p < 0.01 (t test).
(B) Immunofluorescence staining from 3 control induced pluripotent stem cell (iPSC) lines differentiated by expression of the
human Neurogenin 2, Islet 1, and LIM Homeobox 3 (hNIL) transgene cassette. HB9 staining (green) in motor neuron nuclei,
SMI-32 (cyan) in motor neuron processes, and 40,6-diamidino-2-phenylindole (DAPI) staining in blue. Staining is at 5 days
postdifferentiation. Scale bar = 25μm. (C) Western blot analysis of pSMAD2 and SMAD2/3 levels in iPSC motor neurons treated
with 0, 5, and 20ng/ml TGF-β.
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the patients were found to have reduced overall lean body
mass with a z score of <−1. In particular, the average lean
body mass in the extremities was reduced with an average
z score of −1.7. The lower extremities were found to be more
severely involved compared to the upper extremities with
increased fat replacement and average fat z scores of 2.1 and
0.6, respectively. MRI of the Glu385Lys patient showed
muscle loss and diffuse fatty infiltration in muscles of the
thigh and distal lower extremities (Fig 2F), and appendicular
lean body mass was significantly reduced (z score = −5.7)
onDEXA.
Other Findings
Eight patients had benign and malignant tumors, including
5 colonic polyps (1 with polyps of both the uterus and colon),
2 adenocarcinomas of the colon, and 1 of the lung. One
patient with adenocarcinoma of the colon was a 35-year-old
male, a relatively early onset given that the disease frequency
is just 0.4% in men younger than 49 years.14 The benign
polyps were also found in individuals younger than 49 years.
In light of these findings, it is noteworthy that SETX muta-
tions were found in 7% of colorectal tumors in the Cancer
Genome Atlas,15 comparable to the rate of mutations in
DNA mismatch-repair pathway genes MLH1 (3%), MSH3
(7%), andMSH6 (8%).
Characterization of TGF-β Biology in Fibroblasts
and Stem Cell–Derived Motor Neurons
We previously found that the TGF-β pathway is activated
in Leu389Ser ALS4 patient fibroblasts with reduced
expression of BAMBI, a negative regulator of the path-
way.11 Here, we measured and found that the expression
level of BAMBI was also reduced in the patient with
Glu385Lys mutation (p < 0.01; Fig 3). To characterize
the impact of TGF-β on motor neurons, we derived
motor neuron–like cells from control iPSCs. The iPSCs
expressing markers of pluripotency were genotyped to
confirm the stable heterozygous integration of the hNIL
cassette into the CLYBL locus. Motor neuron–like identity
was confirmed by the expression of the homeobox gene
HB916 and the neurofilament marker SMI3217 within
1 week of differentiation.
We treated the iPSC-derived cells with TGF-β and
confirmed activation of the pathway by an increase of
SMAD2 phosphorylation. The neurons with TGF-β treat-
ment showed a significant reduction in neurite length and
branching after 1 week of differentiation (p < 0.0001;
Fig 4A–C), consistent with a toxic effect of TGF-β
activation.
R-Loop Assays
Molecular characterization of patient fibroblasts with the
Leu389Ser mutation previously showed a reduction of nuclear
R loops in patient fibroblasts and motor neurons.11 R loops
are 3-stranded nucleic acid structures that form when nascent
RNA hybridizes with its template DNA to form an RNA–
DNA hybrid and displaces the nontemplate DNA strand.
Senataxin is a helicase that resolves R loops.18,19 An antibody,
S9.6, is used in many studies to characterize R loops.20 To
demonstrate the specificity and sensitivity of the S9.6 antibody
for R loops, we first probed synthetic hybrids of dsRNA,
dsDNA, or RNA–DNA hybrid with the S9.6 antibody
(Fig 5A). S9.6 signal was specific to RNA–DNA hybrid, and
signal intensity was reduced with decreasing amounts of
RNA–DNA hybrid. We evaluated R-loop abundance in the
Glu385Lys patient fibroblasts and found a significant decrease
compared to controls by S9.6 dot blot (p < 0.05; see Fig 5B).
To confirm that the reduction in R-loop abundance is a
consequence of the SETX variant, we overexpressed the WT
and mutant forms of SETX in control fibroblasts. Over-
expression of theGlu385Lys and Leu389Sermutations resulted
in a significant reduction in nuclear R-loop structure by immu-
nofluorescence compared to transfection ofWT senataxin alone
(p < 0.01; see Fig 5C). Overexpression of a 500-amino-acid
N-terminal WT fragment of senataxin without the helicase
domain or other nonpathogenic variants with high allele
FIGURE 4: Morphological analysis of TGF-β–treated motor
neurons. (A) Fluorescence imaging of control motor neuron
lines with and without TGF-β treatment. (B) TGF-β–treated
motor neurons have reduced neurite length and branching.
N = 6, 5 wells analyzed per sample, and error bars are standard
error of the mean. Scale bar = 50μm. ****p < 0.0001 (t test).
[Color figure can be viewedatwww.annalsofneurology.org]
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frequency (Lys827Glu, ExAC allele frequency 0.001) did not
reduce R-loop levels. Dot blot analysis of cells overexpressing
SETX variants, including the previously reported Arg2136His
ALS4 variant,5 showed a reduction in S9.6 signal intensity
when compared toWT SETX (see Fig 5D).
Discussion
Defining the appropriate molecular and clinical biomarkers
for disease characterization and progression are crucial steps
to understanding and treating neurological disease. In this
study, we identified clinical and molecular characteristics of
ALS4 caused by heterozygous mutations in the SETX gene.
Relative to other forms of ALS, the onset for ALS4
is early. The average age of onset in our cohort is 17 years,
which is consistent with the previous clinical characteriza-
tion of patients with mutation at codon 389 of SETX.6,21
In ALS4, males are more affected than females. Rafiq
et al22 also found a significantly greater increase in male
ALS patient serum CK levels compared to females. A pre-
vious study of ALS4 patients found a higher percentage of
asymptomatic females (31%) compared to males (13%).6
As a motor neuron disease, ALS4 leads to progressive
muscle loss. We found significantly higher serum CK and
lower creatinine levels. Elevation of serum CK levels is also
known to occur in patients with sporadic ALS.22 Among
our ALS4 cohort, the male patients had significantly lower
creatinine levels, which reflects a greater disease burden in
males. Serum creatinine levels have been reported to change
significantly during the progression of other motor neuron
diseases.23,24 Radiological studies showed higher thigh mus-
cle fat fraction and lower lean body mass. ALS4 patients
have fatty infiltration in the muscles of their lower extremi-
ties. Previously, we found a reduction in contractile muscle
volume in a smaller cohort of ALS4 patients.11 The pattern
of lean body mass on DEXA analysis supports the finding
that the lower extremities are more severely affected than
the upper extremities. Manual muscle testing also showed a
reduction in lower leg strength with disease duration. The
greater severity of lower extremity involvement in ALS4
was first described by Rabin et al.6 The increased fat
replacement of muscle is likely related to a loss of lean body
mass and disuse and has been found to correlate with dis-
ease status in other studies.25 Together these data suggest
MRI of the lower leg for fatty infiltration to the muscles
may be a useful study to follow for evidence of disease
progression.
FIGURE 5: R-loop assessments of senataxin dysfunction. (A) S9.6 antibody dot blot against a dilution series of synthetic double-
stranded (ds) RNA, dsRNA, and RNA/DNA hybrids. (B) Dot blot probed with S9.6 antibody shows fewer R loops in Glu385Lys
patient fibroblasts compared to 2 age- and sex-matched controls. A duplicate blot probed with anti-dsDNA antibody was used
as loading control. Error bars are standard error of the mean (SEM) of triplicates. *p < 0.05 (t test). (C) Immunofluorescence
staining showing reduced nuclear S9.6 (green) in cells transfected with Leu389Ser and Glu385Lys forms of senataxin (SETX)
compared to wild type (WT). Scale bar = 5μm; R loops in nuclei indicated by arrow. Ten fields per sample, 15 to 20 cells per
field; error bars are SEM. ****p < 0.0001; **p < 0.01 (t test). (D) Quantification of dot blot S9.6 signal in cells transfected with
WT, Leu389Ser, Glu385Lys, and Arg2136His forms of SETX. Samples normalized to dsDNA loading control. Error bars are SEM
of triplicates. *p < 0.05, **p < 0.01 (t test). DAPI = 40,6-diamidino-2-phenylindole.
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We found a similar pattern of clinical and radiologi-
cal changes in a patient with mutation in SETX codon
385. Consistent with the gain of function in SETX heli-
case activity and reduction in R-loop levels that had been
detected in patients with mutation at Leu389Ser,11 the
Glu385Lys SETX variant was also associated with a reduc-
tion in R-loop levels. Expression levels of BAMBI, a nega-
tive regulator of TGF-β activity, were also found to be
reduced in the Glu385Lys SETX patient fibroblasts.
SETX function has been shown to modulate neuro-
muscular junction plasticity in drosophila through the
TGF-β pathway.26 TGF-β signaling has been found to
inhibit neurite elongation and branching in neuronal cell
models27 and to promote disease progression in the
SOD1 mouse model of ALS by disrupting the neuro-
protective functions of activated glial and immune cells.28
Here, we show that exogenous TGF-β treatment of con-
trol iPSC-derived motor neurons resulted in a reduction
in motor neuron neurite length and branching, indicating
that activation of the TGF-β pathway adversely affects
motor neurons.
In conclusion, this study of 32 subjects with muta-
tions in senataxin establishes the clinical and molecular
features of an inherited form of upper and lower motor
neuron disease. We also developed measurement of
R-loop levels and BAMBI expression as assays for interro-
gating the potential pathogenicity of SETX variants. Fur-
ther studies with other mutations in the SETX gene
causing ALS4 are needed to more thoroughly evaluate the
clinical and molecular spectrum. Additional longitudinal
data are also needed to determine the clinical course and
molecular effects and assess heterogeneity of the disease.
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